ClinicalTrials.Veeva

Menu

Longitudinal FolloW-up of Antimicrobial Resistance From Perinatal Acquisition (LWAPA): A SHARE Study ASSESSING AND PREVENTING Antimicrobial Resistance in the Perinatal Period

University of Pennsylvania logo

University of Pennsylvania

Status

Active, not recruiting

Conditions

Drug Resistance, Microbial

Study type

Observational

Funder types

Other

Identifiers

NCT06617260
Antimicrobial resistance(AMR), (Other Identifier)
855283

Details and patient eligibility

About

In 2022, in collaboration between the Botswana Ministry of Health (MOH), the U.S. Centers for Disease Control & Prevention, and the Botswana-UPenn Partnership (BUP), a program was launched called, "Surveillance of Healthcare-associated infections & Antimicrobial Resistance", or "SHARE". The aims of SHARE are to 1) enhance laboratory capacity to detect emerging AMR patterns; 2) strengthen hospital epidemiology programs, leveraging data to prevent, detect, and contain emerging AMR threats; 3) deploy study teams to answer critical public health surveillance questions, and 4) to build a national network of hospital infection prevention and control (IPC) resources to prevent, detect, and contain emerging infectious disease threats.

Full description

The Longitudinal FolloW-up of Antimicrobial Resistance from Perinatal Acquisition (LWAPA) study will assess the extent of perinatally-acquired MDROs and GBS, exploring factors influencing both maternal and neonatal colonization and better understanding the long-term outcomes in families affected by MDRO colonization.

By collecting samples at critical time points (e.g. during labour, after delivery, sequentially in the hospital, and then 3, 6, 9, and 12 months of age, the LWAPA study aims to identify modifiable factors influencing colonization risk. The results from this study can help inform and operationalize infection prevention measures which are poised to reduce the incidence of healthcare-associated infections and other poor health outcomes.

In Setswana, 'lwapa' means 'home' or 'family', which captures how this study aims to understand healthcare-associated AMR is impacting households and communities.

Enrollment

1,000 patients

Sex

Female

Ages

36+ weeks old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Pre-partum mothers will be eligible for recruitment if they have been admitted to the pre-partum ward (2F) at PMH. This includes mothers with:

  • Pre-term labor (24-36 weeks gestation)
  • Pre-eclampsia
  • Post-dates (>41 weeks gestation)-

Exclusion criteria

Mothers/babies who have been admitted for more than 96 hours will be excluded

Trial design

1,000 participants in 1 patient group

Neonates and mothers
Description:
Pre-partum mothers will be eligible for recruitment if they have been admitted to the pre-partum ward (2F) at PMH. This includes mothers with: * Pre-term labor (24-36 weeks gestation) * Pre-eclampsia * Post-dates (\>41 weeks gestation) The rationale for recruiting these mothers is that there is a high probability of having a baby who will ultimately be admitted to the NNU

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems